Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

 
Phase: 1
Protocol No.Title
1999LS073MT1999-20 Hematopoietic cell transplantation in children with juvenile myelomonocytic leukemia
2011OC057MT2011-09C Alkylator-Intense Conditioning Followed By Autologous Transplantation for Patients with High Risk or Relapsed Solid or CNS Tumors
2014IS062An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutation (MEK116540)
2015CG151ADVL1414 - A PHASE 1 STUDY OF SELINEXOR (KPT-330, IND #125052), A SELECTIVE XPO1 INHIBITOR, IN RECURRENT AND REFRACTORY PEDIATRIC SOLID TUMORS, INCLUDING CNS TUMORS
2015IS075HM2015-18: A phase 1/2 study of ALT-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab
2015LS057MT2015-46 : A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma
2015LS057RMT2015-46R: A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma
2015LS167HM2015-39 :GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE(TM)) for the Treatment of High Risk Myelodysplastic Syndromes,Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis
2016IS065An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts
2016IS191A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Pediatrics and Young Adults with no Curative First-Line Treatment Option or Recurrent/Refractory Solid Tumors and Primary CNS Tumors PROTOCOL NUMBER: CO40778 (RXDX-101-03)
2016IS192A Phase I/II, Open-Label, Multicenter, Dose Escalation Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection alone and in Combination with Durvalumab for Patients with Advanced Malignancies
2016IS194A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer
2016LS137Safety of Transarterial Chemoembolization in Patients with Elevated Bilirubin
2017CG087A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors (E7080-A001-216/ADVL1711)
2017CG143COG ADVL1615 - A Phase I Study of Pevonedistat (MLN-4924, IND#136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors Additional Title: "COG ADVL1615 - Millennium Pharmaceuticals, Inc."
2017IS028Phase 1 Trial of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta (VSV-IFN-NIS) Monotherapy and in Combination with Avelumab, in Patients with Refractory Solid Tumors
2017IS061MT2017-36 :FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors
2017IS090SGN22E-002: A dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with pembrolizumab and/or chemotherapy for treatment of patients with locally advanced or metastatic urothelial cancer
2017IS140A phase 1B/2 study to evaluate safety and anti-tumor activity of avelumab in combination with the poly (adenosine diphosphate [adp]-ribose) polymerase (parp) inhibitor talazoparib in patients with locally advanced or metastatic solid tumors
2017IS157MT2017-43 A phase I study of Neihulizumab (AbGn-168H) in patients with steroid-refractory acute graft-versus-host disease (sr-aGvHD)
2017LS006HM2017-24 :Phase I Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma
2017LS075Phase 1 Trial of Indole-3-Carbinol and Silibinin
2017NTUC086Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect
2018CG056A Non-Randomized, Open-Label, Multi-center, Phase I/II Study of PI3K inhibitor Copanlisib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Lymphoma (BAY 80-6946 /19176/ADVL1721)
2018IS003A PHASE 1/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-262 IN COMBINATION WITH NKTR-214 AND IN COMBINATION WITH NKTR-214 PLUS NIVOLUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
2018IS079MT2018-14 :An interventional, multicenter, single arm, phase I/IIA clinical trial to investigate the efficacy and safety of Allo-APZ2-EB on Epidermolysis Bullosa (EB)
2018IS116MT2018-25 :Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)
2018IS141MT2019-29 FT500 as Monotherapy and in Combination with Immune Checkpoint Inhibitors in Subjects with Advanced Solid Tumors (Phase 1)
2018IS157HM2018-32 A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
2018IS166HM2018-34 A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin s Lymphoma
2018UC048A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma (PNOC013)
2018UC095A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-127
2018UC137HM2018-30: Phase I/II Study of Ixazomib and Romidepsin in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL): Big Ten Cancer Research Consortium BTCRC-HEM15-028
2019CG103COG ADVL1712 - A Feasibility Trial of MLN4924 (Pevonedistat,TAK924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed Myelodysplastic Syndrome
2019IS108MT2019-25 :A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma
2019IS147RAMP: A Phase 1b, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
MT2009-09MT2009-09 Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Stem Cell Transplantation
PEDS-2019-27873A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects with Fabry Disease
PSYCH-2019-27460How Does the Brain Discriminate Between Internally- and Externally- Generated Stimuli?
PSYCH-2019-27473Precision Mental Health for Pregnant Women and Mothers: Addressing Unmet Cognitive Needs
PSYCH-2019-27663Brain Imaging-Based Care in Psychiatry (BIBCaP)